Sinopharm Group Co. Ltd. (HKG:1099)
Hong Kong · Delayed Price · Currency is HKD 19.22
-0.34 (-1.74%)
Apr 24, 2026, 4:08 PM HKT
Sinopharm Group Income Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
| 574,698 | 575,168 | 584,508 | 596,570 | 552,148 | 521,051 | |
Revenue Growth (YoY) | -0.73% | -1.60% | -2.02% | 8.04% | 5.97% | 14.16% |
Cost of Revenue | 533,088 | 533,496 | 540,253 | 548,058 | 504,713 | 477,001 |
Gross Profit | 41,609 | 41,672 | 44,255 | 48,512 | 47,434 | 44,051 |
Selling, General & Admin | 24,026 | 24,026 | 25,582 | 26,161 | 24,914 | 23,210 |
Other Operating Expenses | -428.51 | -428.51 | -468.62 | -582.01 | -676.16 | -589.19 |
Operating Expenses | 24,442 | 24,442 | 26,436 | 26,193 | 24,670 | 23,067 |
Operating Income | 17,167 | 17,230 | 17,819 | 22,318 | 22,764 | 20,984 |
Interest Expense | -2,293 | -2,293 | -2,724 | -2,946 | -3,509 | -3,745 |
Interest & Investment Income | 510.18 | 510.18 | 621.38 | 783.41 | 555.82 | 590.55 |
Earnings From Equity Investments | 1,233 | 1,233 | 1,199 | 1,107 | 1,067 | 1,070 |
Currency Exchange Gain (Loss) | 0.93 | 0.93 | -15.62 | -9.98 | -2.39 | -10.51 |
Other Non Operating Income (Expenses) | -413.92 | -415.01 | -331.44 | -291.8 | -464.32 | -339.47 |
EBT Excluding Unusual Items | 16,204 | 16,265 | 16,568 | 20,962 | 20,411 | 18,549 |
Impairment of Goodwill | -459.73 | -459.73 | -931.2 | -27.02 | -38.98 | -396.06 |
Gain (Loss) on Sale of Investments | -1,046 | -1,046 | -1,650 | -1,986 | -1,892 | -1,094 |
Gain (Loss) on Sale of Assets | 20.53 | 20.53 | 79.91 | 492.31 | 3.11 | 65.87 |
Asset Writedown | -101.17 | -101.17 | -174.76 | -27.88 | -16.81 | -210.8 |
Other Unusual Items | 120.81 | 120.81 | 108.08 | 98.92 | 97.81 | 88.71 |
Pretax Income | 14,738 | 14,800 | 14,001 | 19,512 | 18,564 | 17,003 |
Income Tax Expense | 3,944 | 3,965 | 3,577 | 4,502 | 4,218 | 3,938 |
Earnings From Continuing Operations | 10,794 | 10,834 | 10,424 | 15,010 | 14,345 | 13,065 |
Minority Interest in Earnings | -3,679 | -3,679 | -3,374 | -5,956 | -5,820 | -5,306 |
Net Income | 7,115 | 7,155 | 7,050 | 9,054 | 8,526 | 7,759 |
Net Income to Common | 7,115 | 7,155 | 7,050 | 9,054 | 8,526 | 7,759 |
Net Income Growth | 0.40% | 1.49% | -22.13% | 6.19% | 9.89% | 7.95% |
Shares Outstanding (Basic) | 3,120 | 3,121 | 3,121 | 3,121 | 3,117 | 3,121 |
Shares Outstanding (Diluted) | 3,120 | 3,121 | 3,121 | 3,121 | 3,117 | 3,121 |
Shares Change (YoY) | -0.13% | - | - | 0.12% | -0.12% | 0.30% |
EPS (Basic) | 2.28 | 2.29 | 2.26 | 2.90 | 2.74 | 2.49 |
EPS (Diluted) | 2.28 | 2.29 | 2.26 | 2.90 | 2.74 | 2.49 |
EPS Growth | 0.52% | 1.49% | -22.10% | 6.02% | 10.02% | 7.63% |
Free Cash Flow | - | 12,221 | 10,075 | 15,213 | 18,837 | 7,234 |
Free Cash Flow Per Share | - | 3.92 | 3.23 | 4.88 | 6.04 | 2.32 |
Dividend Per Share | 0.690 | 0.690 | 0.680 | 0.870 | 0.820 | 0.750 |
Dividend Growth | 1.47% | 1.47% | -21.84% | 6.10% | 9.33% | 8.70% |
Gross Margin | 7.24% | 7.25% | 7.57% | 8.13% | 8.59% | 8.45% |
Operating Margin | 2.99% | 3.00% | 3.05% | 3.74% | 4.12% | 4.03% |
Profit Margin | 1.24% | 1.24% | 1.21% | 1.52% | 1.54% | 1.49% |
Free Cash Flow Margin | - | 2.13% | 1.72% | 2.55% | 3.41% | 1.39% |
EBITDA | 19,451 | 19,487 | 19,971 | 24,404 | 24,777 | 22,896 |
EBITDA Margin | 3.38% | 3.39% | 3.42% | 4.09% | 4.49% | 4.39% |
D&A For EBITDA | 2,284 | 2,257 | 2,151 | 2,085 | 2,012 | 1,912 |
EBIT | 17,167 | 17,230 | 17,819 | 22,318 | 22,764 | 20,984 |
EBIT Margin | 2.99% | 3.00% | 3.05% | 3.74% | 4.12% | 4.03% |
Effective Tax Rate | 26.76% | 26.79% | 25.55% | 23.07% | 22.72% | 23.16% |
Updated Mar 31, 2026. Source: S&P Global Market Intelligence. Standard template. Financial Sources.